Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S11–S15 | Cite as

Resistance to quinolones

  • R. P. Mouton


Resistance to quinolones is only due to mutations. The mechanism and the range of quinolones involved, depend on the locus of the chromosomal mutation e.g. a mutation in the gyr A locus is associated with resistance due to changes in the gyrase. Using high inoculain vitro, varying, but relatively low mutation rates of resistance to fluoroquinolones have been found (10−6-10−12).In vitro transfers of bacterial strains in increasing concentrations of quinolones yield parallel increases of the MIC's of most quinolones; however, the MIC's of the most active quinolones like ciprofloxacin usually remain below concentrations achievablein vivo. Exceptions are MIC's forPseudomonas aeruginosa and staphylococci. Combined resistance to quinolones and other antibiotics was observed afterin vitro transfers as well as in mutants (10−6-10−8) isolated from a high inoculum. Changes in the outer membrane proteins have been found in these mutants. Clinical resistance to fluoroquinolones is rare except inPseudomonas aeruginosa and staphylococci.

Key words

Combined resistance Drug resistance Mechanisms of resistance Quinolones 


  1. 1.
    Bachmann BJ, Low KB, Tylor AL. Recalibrated linkage map ofEscherichia coli K-12. Bact Rev 1976;40:1 16–67.Google Scholar
  2. 2.
    Hirai K, Aoyama H, Suzue S, Irikura T, Iyobe S, Mitsuhashi S. Isolation and characterization of norfloxacin-resistant mutantsof Escherichia coli K-12. Antimicrob Agents Chemother 1986;30:248–53.PubMedGoogle Scholar
  3. 3.
    Kayser FH. The quinolones: mode of action and mechanism of resistance. Research Clinical Forums 1985;7:17–27.Google Scholar
  4. 4.
    Ronald AR, Turck M, Petersdorf RG. A critical evaluation of nalidixic acid in urinary tract infections. N Engl J Med 1966;297:1081–9.Google Scholar
  5. 5.
    Duckworth GJ, Williams JD. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid. J Antimicrob Chemother 1984;13 suppl B:33–8.PubMedGoogle Scholar
  6. 6.
    Cullman W, Stieglitz M, Baars B, Opferkuch W. Comparative evaluation of recently developed quinolone compoundss-with a note on the frequency of resistant mutants. Chemother 1985;31:19–28.Google Scholar
  7. 7.
    Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986;18 suppl D:21–9.PubMedGoogle Scholar
  8. 8.
    Sanders CC, Sanders WE, Goering RV, Werner V. Selection of multiple antibiotic resistance by quinolones, betalactams and aminoglycosides with special reference to crossresistance between unrelated drug classes. Antimicrob Agents Chemother 1984;26:797–801.PubMedGoogle Scholar
  9. 9.
    Lerner SA, Lavieri CA, Quimosing EM. Selection of ciprofloxacin-resistant mutantsin vitro from clinical isolates ofPseudomonas aeruginosa. Abstr. Int Symp on New Quinolones; Geneva 1986:19.Google Scholar
  10. 10.
    Haller I. Quantitative analysis of spontaneous mutations inSerratia marcescens which affect susceptibility to quinolones in different ways. Proceedings of the 14th International Congress of Chemotherapy; Kyoto 1985:1869–70.Google Scholar
  11. 11.
    Kayser FH, Morenzoni G. In vitro activity of 4-quinolones against difficult-to-treat organisms and development of resistance to these drugs. Proceedings of the 14th International Congress of Chemotherapy; Kyoto 1985:1863–4.Google Scholar
  12. 12.
    Scribner RK, Welch DF, Marks MI. Low frequency of bacterial resistance to enoxacinin vitro and in experimental pneumonia. J. Antimicrob Chemother 1985;16:597–603.PubMedGoogle Scholar
  13. 13.
    Mouton RP, Mulders SLTA. Combined resistance to quinolones and beta-lactams afterin vitro transfer on single drugs. Chemother 1987;33:189–196.Google Scholar
  14. 14.
    Piddock LJV, Diver JM, Wise R. Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials. Eur J Clin Microbiol 1986;5:411–5.PubMedGoogle Scholar
  15. 15.
    Chapman ST, Speller DCE, Reeves DS. Resistance to ciprofloxacin. Lancet 1985;2:39.Google Scholar
  16. 16.
    Roberts CM, Batten J, Hodson ME. Ciprofloxacin-resistantPseudomonas. Lancet 1985;1:1442.Google Scholar
  17. 17.
    Follath F, Bindschedler M, Wenk M, Frei R, Stalder H, Reber H. Use of ciprofloxacin in the treatment ofPseudomonas aeruginosa infections. Eur J Clin Microbiol 1986;5:236–40.PubMedGoogle Scholar
  18. 18.
    Humphreys H, Mulvihill E. Ciprofloxacin-resistantStaphylococcus aureus. Lancet 1985;2:383.Google Scholar
  19. 19.
    Smith GM, Cashmore C, Leyland MJ. Ciprofloxacin-resistant staphylococci. Lancet 1985;2:949.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • R. P. Mouton
    • 1
  1. 1.Department of Medical MicrobiologyUniversity HospitalRC LeidenThe Netherlands

Personalised recommendations